跳至主要内容
临床试验/EUCTR2012-003688-24-NL
EUCTR2012-003688-24-NL进行中(未招募)不适用

Treatment of Complex Regional Pain Syndrome type 1: A randomized placebo controlled double-blind study with ARA 290 - CRPSARA

eiden University Medical Center0 个研究点开始时间: 2012年9月18日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • (1) Continuing pain, which is disproportionate to any inciting event;
  • (2) Must report at least one symptom in three of the four following categories:
  • a. Sensory: reports of hyperesthesia and/or allodynia;
  • b. Vasomotor: reports of temperature asymmetry and/or skin color changes and/or color asymmetry;
  • c. Sudomotor/edema: reports of edema and/or sweating changes and sweating asymmetry;
  • d. Motor/trophic: reports of decreased motor ranges and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin);
  • (3) Must display at least one sign at time of evaluation in two or more of the following categories:
  • a. Sensory: hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement);
  • b. Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or color asymmetry;
  • c. Sudomotor/edema: evidence of edema and/or sweating changes and sweating asymmetry;
  • d. Motor/trophic: evidence of decreased motor ranges and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin);
  • (4) There is no other diagnosis that better explains the signs and symptoms.
  • (5) Pharmacotherapy for CRPS symptoms (e.g., analgesics, antidepressants, and/or anticonvulsants ) has been stable for at least 4 weeks
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Inability to give informed consent;
  • Patients suffering from other pain syndromes;
  • Clinically relevant abnormal history of physical and mental health, as determined by medical history taking and physical examinations obtained during the screening visit and/or prior to the administration of the initial dose of the study drug (as judged by the investigator);
  • A semi recumbent systolic blood pressure of >160 mmHg and/or diastolic blood pressure of > 95 mmHg at screening;
  • History of alcoholism or substance abuse within three years prior to screening;
  • Positive pregnancy test or lactation
  • Male subjects habitually using more than 21 units of alcohol per week and female subjects using more than 14 units of alcohol per week;
  • Subject has a history of severe allergies, or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food;
  • Subjects that received a vaccination or immunization within the last month;
  • Participation in an investigational drug trial in the 3 months prior to administration of the initial dose of study drug or more than 4 times per year;
  • Subject has undergone major surgery within three months prior to screening;
  • Inability or unwillingness to self-administer ARA 290 via subcutaneous injections
  • Any other condition that in the opinion of the investigator would complicate or compromise the study, or the well being of the subject

研究者

发起方
eiden University Medical Center

相似试验